Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Di Maio

Showing results (171-180 of 418) with videos related to

Pageof 42
Sort By:
Prostate Cancer and Prostatic Diseases|December 14, 2023
Safety profile of darolutamide versus placebo: a systematic review and meta-analysisFabio Turco, Silke Gillessen, Giorgio Treglia, et al.
Lung Cancer (Amsterdam, Netherlands)|July 13, 2026
Germline testing in lung cancer: evidence of enrichment without a standardized selection strategy - a systematic reviewFabrizio Citarella, Roberto Ferrara, Massimo Di Maio, et al.
JCO Oncology Practice|June 24, 2020
Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research ActivitiesFrancesca Poggio, Marco Tagliamento, Massimo Di Maio, et al.
Breast (Edinburgh, Scotland)|January 18, 2025
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancerPaola Zagami, Angela Esposito, Beatrice Taurelli Salimbeni, et al.
The Oncologist|April 8, 2009
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directionsAlessandro Morabito, Maria Carmela Piccirillo, Fabiano Falasconi, et al.
Lung Cancer (Amsterdam, Netherlands)|July 18, 2008
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trialVittorio Gebbia, Cesare Gridelli, Claudio Verusio, et al.
Minerva Urology and Nephrology|March 30, 2021
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamideChiara Pisano, Marcello Tucci, Rosario F DI Stefano, et al.
JCO Oncology Practice|July 6, 2021
Descriptive Comparative Analysis of Patients With Cancer Referring to the Emergency Department of an Italian University Hospital Across the Severe Acute Respiratory Syndrome Coronavirus 2 WavesAnnapaola Mariniello, Paolo Bironzo, Chiara Pisano, et al.
Expert Review of Anticancer Therapy|October 19, 2013
Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectivesRaffaele Costanzo, Agnese Montanino, Massimo Di Maio, et al.
Minerva Urology and Nephrology|February 11, 2022
Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective studyTiziana Angusti, Rosario F DI Stefano, Antonella Parente, et al.
Pageof 42

Showing results (171-180 of 418) with videos related to

Sort By:
Pageof 42
Prostate Cancer and Prostatic Diseases|December 14, 2023
Safety profile of darolutamide versus placebo: a systematic review and meta-analysisFabio Turco, Silke Gillessen, Giorgio Treglia, et al.
Lung Cancer (Amsterdam, Netherlands)|July 13, 2026
Germline testing in lung cancer: evidence of enrichment without a standardized selection strategy - a systematic reviewFabrizio Citarella, Roberto Ferrara, Massimo Di Maio, et al.
JCO Oncology Practice|June 24, 2020
Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research ActivitiesFrancesca Poggio, Marco Tagliamento, Massimo Di Maio, et al.
Breast (Edinburgh, Scotland)|January 18, 2025
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancerPaola Zagami, Angela Esposito, Beatrice Taurelli Salimbeni, et al.
The Oncologist|April 8, 2009
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directionsAlessandro Morabito, Maria Carmela Piccirillo, Fabiano Falasconi, et al.
Lung Cancer (Amsterdam, Netherlands)|July 18, 2008
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trialVittorio Gebbia, Cesare Gridelli, Claudio Verusio, et al.
Minerva Urology and Nephrology|March 30, 2021
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamideChiara Pisano, Marcello Tucci, Rosario F DI Stefano, et al.
JCO Oncology Practice|July 6, 2021
Descriptive Comparative Analysis of Patients With Cancer Referring to the Emergency Department of an Italian University Hospital Across the Severe Acute Respiratory Syndrome Coronavirus 2 WavesAnnapaola Mariniello, Paolo Bironzo, Chiara Pisano, et al.
Expert Review of Anticancer Therapy|October 19, 2013
Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectivesRaffaele Costanzo, Agnese Montanino, Massimo Di Maio, et al.
Minerva Urology and Nephrology|February 11, 2022
Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective studyTiziana Angusti, Rosario F DI Stefano, Antonella Parente, et al.
Pageof 42